Objective Response Rate of Ivonescimab With Chemotherapy in Locally Advanced Resectable Oral and Oropharyngeal Squamous Cell Carcinoma

NCT07686575 · clinicaltrials.gov ↗

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

HNSCC
OSCC
OPSCC
Ivonescimab

Interventions

DRUG: Ivonescimab（AK112，a PD-1/VEGF bispecific antibody）

Sponsor

Zhujiang Hospital